Canine TARC Blood Testing for Atopic Dermatitis Differentiation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for diagnosing and treating canine atopic dermatitis-like skin symptoms in dogs are inefficient, costly, and risky due to the difficulty in differentiating it from similar skin conditions, leading to prolonged treatment durations and potential side effects.

Innovation Solution

A method and reagent using TARC levels in blood samples to determine whether a dog has atopic dermatitis or a different condition by measuring TARC levels and setting a threshold value, with treatments tailored accordingly.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional skin condition diagnosis methods are used, then treatment can be provided, but accurate differentiation of atopic dermatitis from other skin conditions is difficult, leading to prolonged treatment duration and potential side effects

Engineering Contradiction:

Improvediagnosis accuracyVSAvoidtreatment duration

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent performs preliminary measurement of TARC levels in blood samples before initiating treatment. By measuring the thymus and activation-regulated chemokine (TARC) concentration in advance, the method enables early differentiation of atopic dermatitis from other skin conditions, allowing appropriate treatment to start immediately without prolonged diagnostic uncertainty or trial-and-error approaches

Inventive Principle:

Principle #10Preliminary action

2Measurement precision

If conventional skin condition diagnosis methods are used, then treatment can be provided, but differentiation from other similar skin conditions is difficult, leading to increased treatment cost

Engineering Contradiction:

Improvediagnosis accuracyVSAvoidtreatment cost

Core Design Contradiction:

Measurement precisionVSLoss of energy

Solution Approach 1:

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses TARC (thymus and activation-regulated chemokine) as an intermediary biomarker to differentiate atopic dermatitis from other skin conditions. By measuring TARC levels in blood samples, the method provides an objective indicator that mediates between the clinical presentation and the underlying diagnosis, enabling accurate differentiation without requiring complex or multiple diagnostic procedures

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables early and accurate differentiation of atopic dermatitis from other skin conditions, reducing treatment duration, cost, and side effects by directly targeting appropriate therapies.

Implementation Method 1

measuring a level of TARC comprised in a blood sample collected from the subject using an antibody that specifically binds to canine TARC

Methodology Applied

Scientific EffectAntibody binding:

Data Source

PatentEP4592677A1Method for assisting in determining treatment plan for dog having skin condition

Publication Date: 2025.07.30 NIPPON ZENYAKU KOGYO CO LTD

AI summary

Provided is a method for assisting in determining a treatment strategy for a dog with an atopic dermatitis-like skin symptom by using an objective indicator based on a blood test. Provided is a method comprising the following steps: step a) of measuring a level of TARC comprised in a blood sample collected from the subject; and step b) of determining that treatment for atopic dermatitis is useful when the level of TARC is equal to or greater than a threshold value, and determining that treatment for a different disease is useful when the level of TARC is less than the threshold value.